The information about the relationship between specific mutations in BRCA1/2 and the clinical expression is limited; however, there is evidence that mutations in the central part of BRCA2 (around exon 11), defined as the Ovarian Cancer Cluster Region, are associated with a higher OC risk and lower BC risk [32, 33]. The gene discussed is BRCA2; the disease is ovarian carcinoma.